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The development of new techniques to study glial cells has revealed that they are active
participants in the development of functional neuronal circuits. Calcium imaging studies
demonstrate that glial cells actively sense and respond to neuronal activity. Glial cells can
produce and release neurotransmitter-like molecules, referred to as gliotransmitters, that
can in turn inﬂuence the activity of neurons and other glia. One putative gliotransmitter,
D-serine is believed to be an endogenous co-agonist for synaptic N -methyl-D-aspartate
receptors (NMDARs), modulating synaptic transmission and plasticity mediated by this
receptor.The observation that D-serine levels in the mammalian brain increase during early
development, suggests a possible role for this gliotransmitter in normal brain development
and circuit reﬁnement. In this review we will examine the data that D-serine and its
associated enzyme serine racemase are developmentally regulated. We will consider the
evidence that D-serine is actively released by glial cells and examine the studies that have
implicated D-serine as a critical player involved in regulating NMDAR-mediated synaptic
transmission and neuronal migration during development. Furthermore, we will consider
how dysregulation of D-serine may play an important role in the etiology of neurological
and psychiatric diseases.
Keywords: gliotransmission, D-serine, NMDA receptors, schizophrenia, depression and anxiety disorders, neural
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INTRODUCTION
Two decades ago a revolutionary discovery identiﬁed the presence
of the D-amino acid D-serine in mammalian brain. The discovery
that D-serine is an abundant amino acid in the brains of rodents
and humans led to extensive experimental inquiry into how this
amino acid, which was previously thought to have no speciﬁc bio-
logical function, might be involved in normal brain development
and function. In this review we will consider the development
of analytical techniques that have been used to identify and
localize D-serine within mammalian brains and review what is
now known about its important biological function during brain
development.
D-SERINE LOCALIZATION WITHIN GLIA IN SPECIFIC BRAIN AREAS IN
PROXIMITY TO NMDARs
With the development of sensitive analytical techniques, such
as gas chromatography and mass spectrometry, D-serine was
discovered in mammalian brains about 20 years ago. In partic-
ular, Hashimoto et al. (1992) showed, using these two techniques,
that D-serine was present in rodent and human brains at signif-
icantly higher concentrations than other D-amino acids, such as
D-aspartate and D-alanine (Hashimoto et al., 1992, 1993a). More-
over, they showed that the distribution of D-serine paralleled the
distribution of N-methyl-D-aspartate (NMDA) type glutamate
receptors (Hashimoto et al., 1993a; Figures 1A and B). While
previous work had determined that D-amino acids were capa-
ble of binding the glycine modulatory site of the NMDA receptor
(Kleckner and Dingledine, 1988), the ﬁndings of Hashimoto et al.
(1992, 1993a,b) pointed to D-serine as a potential endogenous
co-ligand for the NMDA receptor. This role for D-serine as an
endogenous NMDA receptor co-ligand helped explain the obser-
vation that glycine is not typically enriched in brain regions that
have high levels of NMDA receptor expression (Schell et al., 1997;
Figure 1C). Furthermore, D-amino acid oxidase (DAAO), the
enzyme that degrades D-serine, had been discovered in mam-
mals (Weimar and Neims, 1977; Horiike et al., 1987) before this
demonstration of endogenous D-serine. Thus, with the discovery
of D-serine, the ability of endogenous NMDA receptors to func-
tion in the absence of glycine and the presence of DAAO in the
central nervous system (CNS) were both demystiﬁed.
Since the initial detection of D-serine in the CNS, subsequent
immunostaining studies have more precisely localized D-serine
and DAAO within speciﬁc brain areas and speciﬁc cell types. In
the adult brain, areas with particularly high levels of NMDARs,
including the cerebral cortex, hippocampus, thalamus, hypotha-
lamus, amygdala, and retina are enriched in D-serine whereas
other brain regions, such as the hindbrain, pons, and medulla
have virtually undetectable levels of D-serine (Schell et al., 1995).
Intriguingly, the localization of DAAO is opposite that of D-serine;
areas including the cortex, which have high levels of D-serine have
very low levels of DAAO.
After looking more closely at the distribution of D-serine
amongst different cell types Schell et al. (1995) made the strik-
ing and important discovery that D-serine is localized principally
within glial cells. Speciﬁcally, they found that type-2 astrocytes,
cultured from cerebral cortex, expressed particularly high levels of
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FIGURE 1 | Immunohistochemical staining of (A) D-serine, (B) NMDAR
subunits GluN2A/B, and (C) glycine in rat brains (P21). Am, amygdala;
Cl, claustrum; Cx, cortex; EPL, external plexiform layer; Hb, habenula; Hy,
hippocampus; PM, pons/medulla; Sn, substantia nigra; Sp, spinal cord;
WM, white matter; VNL, vomeronasal nerve layer. Figure modiﬁed from
Schell et al. (1997).
D-serine. Additional studies in other brain areas have also localized
D-serinewithin astrocytes. In the retina, Stevens et al. (2003) found
D-serine in astrocytes and Müller glia cells. Furthermore, studies
in the hippocampus, hypothalamus, vestibular nuclei (VN), and
cerebellum have all placed the main expression of D-serine within
glia cells (Mothet et al., 2000; Kim et al., 2005; Panatier et al., 2006;
Puyal et al., 2006). Accumulating evidence, however, suggests that
the synthesis, storage, and release of D-serine may not be limited
exclusively to astrocytes, but rather may involve distinct functions
for different cells.
D-SERINE SYNTHESIS AND DEGRADATION
The key enzyme thought to be responsible for the synthesis of
D-serine is serine racemase (SR). SR, which converts L-serine to
D-serine, was initially found in astrocytes and microglia in the
mammalian brain (Wolosker et al., 1999; Stevens et al., 2003; Wu
et al., 2004; Panatier et al., 2006). More recently, however, SR was
also identiﬁed in neurons (Kartvelishvily et al., 2006; Yoshikawa
et al., 2007; Dun et al., 2008; Miya et al., 2008; Wolosker et al.,
2008; Rosenberg et al., 2010) challenging the traditional view that
D-serine is generated solely by astrocytes. In fact, SR was found
to be expressed at signiﬁcantly higher levels in neurons than in
astrocytes. A study that compared SR and D-serine levels in cell
type-speciﬁc SR knockout mice found that SR levels were lower in
mice with neuronal knockout of SR than in mice with astrocyte-
speciﬁc knockout of SR (Benneyworth et al., 2012). Surprisingly,
despite a signiﬁcant reduction of SRprotein in neuronal SR knock-
out mouse brains, D-serine levels were only minimally reduced
indicating that neurons are not the sole source of D-serine.
REGULATION OF SR
A number of proteins that interact directly with SR have been
identiﬁed, including the Golgin subfamily A member 3 protein
(Dumin et al., 2006), the glutamate receptor interacting protein
(GRIP; Kim et al., 2005), and the protein interacting with C-kinase
1 (PICK1; Fujii et al., 2006; Hikida et al., 2008). Furthermore, a
more recent study showed that protein kinase C (PKC), which
interacts directly with PICK1, is able to phosphorylate SR, leading
to a corresponding decrease in D-serine levels in vitro and in vivo
(Vargas-Lopes et al., 2011). There is also evidence suggesting that
activation of erythropoietin-producing hepatocellular carcinoma
(Eph) receptors decreases interaction between Eph–PICK1 and
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instead favors the SR–PICK1 interaction, resulting in a subsequent
increase in D-serine synthesis in cultured hippocampal astrocytes
(Zhuang et al., 2010).
THE D-SERINE SHUTTLE HYPOTHESIS
In addition to catalyzing the conversion of L-serine to D-serine,
SR can also cause the degradation of serine through the bio-
chemical elimination of water, resulting instead in the pro-
duction of pyruvate and ammonia (De Miranda et al., 2002).
This degradation function of SR is likely to be important
in regions of the brain, including the forebrain, that have
with low levels of DAAO expression (Hashimoto et al., 1993b;
Nagata et al., 1994). Astrocytes, having lower levels of SR com-
pared to neurons, would be ideally suited for the safe stor-
age of D-serine, effectively sequestering it from degradation by
neuronal SR.
Interestingly, L-serine and its precursors are not abundant in
neurons but found primarily in glial cells suggesting that although
neurons have high levels of SR they require an external source of L-
serine. For example, 3-phosphoglycerate dehydrogenase (Phgdh)
an enzyme that catalyzes the formation of L-serine from glucose
is localized almost exclusively in astrocytes (Furuya et al., 2000;
Yamasaki et al., 2001) and a recent study has shown that a condi-
tional deletion of Phgdh results in a signiﬁcant decrease in both
L- and D-serine levels in adult cerebral cortex and hippocampus
(Yang et al., 2010). It has been suggested that the biosynthetic path-
way for L-serine may be located in astrocytes but not neurons,
requiring the transport of astrocytic L-serine to neurons where it
can then be converted to D-serine for subsequent storage back in
astrocytes.
Taken together there is accumulating evidence supporting a
“D-serine shuttle hypothesis” which proposes that D-serine syn-
thesized in neurons is shuttled to astrocytes where it is stored and
released (Wolosker, 2011; Figure 2). Amino acid transporters have
been identiﬁed in astrocytes and neurons (Yamamoto et al., 2004)
and are thought to play an important role the transfer of amino
acids between neurons and glia. Speciﬁcally, Na+-dependent
ASCT1 and ASCT2 and Na+-independent alanine–serine–cystein
transporter-1 (Asc-1) are two types of transporters that regulate
D-serine levels. Of these, Asc-1, which is found exclusively in neu-
rons, has a higher afﬁnity for D-serine than ASCT1 and ASCT2
(Fukasawa et al., 2000; Helboe et al., 2003) and activation of Asc-1
by D-isoleucine has recently been shown to increase D-serine lev-
els and to play a role in modulating synaptic plasticity (Rosenberg
et al., 2013).
While it is generally agreed that astrocytic D-serine is necessary
for normal glutamatergic transmission, the relative contribution
of neuron- versus astrocyte-derivedD-serine remains controversial
and is likely to change over development and to differ by brain
region.
RELEASE OF D-SERINE
A number of studies have now clearly shown that the
release of D-serine from astrocytes can be stimulated with the
application of non-NMDA glutamate receptor agonists (Schell
et al., 1995; Ribeiro et al., 2002; Mothet et al., 2005; Sullivan and
Miller, 2010).
Using a sensitive chemoluminescence assay,Mothet et al. (2005)
were able to demonstrate that D-serine release from cortical
cultured astrocytes is evoked by glutatmate, α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA) or kainic acid appli-
cation, and is inhibited in the presence of AMPA blockers. The
AMPA-evoked release of D-serine has been further supported by
studies in other brain areas. Using capillary electrophoresis in
the intact retina Sullivan and Miller (2010) have shown AMPA
stimulates D-serine release and that release is abolished in the
presence of a glial toxin. Furthermore, in primary glial cultures
from cerebellum, activation of α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate receptors (AMPARs) has also been shown to
trigger activation of SR by binding to GRIP to drive subsequent
efﬂux of D-serine (Kim et al., 2005).
One important but somewhat contentious observation is the
ﬁnding that release of D-serine from astrocytes may involve
vesicular trafﬁcking. Using the chemiluminescence assay for mea-
suring D-serine, Mothet et al. (2005) found evidence that D-serine
release is a SNARE (soluble NSF attachment protein receptor)
protein-dependent process that requires calcium inﬂux. D-serine
release from astrocytes is impaired by applying tetanus toxin light
chain, an endopeptidase that cleaves SNARE proteins necessary
for vesicular fusion (Martineau et al., 2008). Furthermore, more
recent studies in hippocampal slices have provided additional
evidence that at least some of astrocytic D-serine release relies
on vesicle-associated membrane protein (VAMP)-dependent exo-
cytosis (Henneberger et al., 2010). In contrast, Rosenberg et al.
(2010) showed that activation of volume-regulated anion chan-
nels (VRACs) resulted in a signiﬁcant amount of D-serine released
from astrocytic cultures, but that blocking vesicular ﬁlling using
baﬁlomycin and concanamycin, which are inhibitors of vacuolar
ATPase, did not affect D-serine release. Notably, Rosenberg et al.
(2010) highlighted the fact that while both neurons and astrocytes
can release D-serine, the mechanisms mediating D-serine release
from neurons are likely to be different from those in astrocytes.
They found that depolarization of neurons in cortical slices using
veratridine, which induced D-serine release by neurons but not
by astrocytes, resulted in 10-fold greater levels of D-serine release
than AMPA receptor activation, which is thought to evoke release
from astrocytes.
A recent series of studies has provided new lines of evidence
that astrocytes and neurons can release D-serine through different
mechanisms. In particular, a detailed analysis of the contents of
rat cortical astrocytes has revealed that these cells contain storage
vesicles that share features similar to synaptic vesicles. Moreover,
they found that cortical astrocytic vesicles contain high levels of D-
serine, in addition to other neuromodulators including glutamate
and glycine (Martineau et al., 2013). In contrast, Rosenberg et al.
(2013) has used both cultured cells and acute hippocampal slices to
demonstrate thatAsc-1 mediates release of D-serine from cytosolic
pools in neurons.
Additional studies are still needed to determine the relative
importance and function of astrocytic versus neuronal D-serine.
To date, much of what is known about D-serine release comes
from in vitro studies but it will become increasingly important
to accurately measure D-serine concentrations in vivo. For exam-
ple, in vivo microdialysis has been used to measure extracellular
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 39 | 3
“fncel-07-00039” — 2013/4/22 — 12:29 — page 4 — #4
Van Horn et al. D-serine in development and disease
FIGURE 2 | Schematic model of the proposed pathways mediating
D-serine synthesis and release. Activation of presynaptic neuron results in
release of glutamate that binds to AMPA receptors on neighboring astrocytes
and causes release of D-serine. D-serine released from astrocytes binds to
synaptic NMDAR-containing GluN2A subunits. Extrasynaptic receptors
containing GluN2B preferentially bind glycine instead of D-serine. SR localized
in neurons synthesizes D-serine from L-serine. L-serine is shuttled to neurons
from astrocytes through amino acid transporters (ASCT). SR is also
responsible for the degradation of serine resulting in production of pyruvate
and ammonia.
concentrations of D-serine in mouse barrel cortex (Takata et al.,
2011). It was found that stimulation of the nucleus basalis of
Meynert resulted in an increase in D-serine concentration that
could not be induced in inositol-1,4,5-trisphosphate receptor type
2 knockout mice, in which astrocytic calcium ﬂuctuations are
reduced.
Recently, implantable amperometric biosensors have been
developed which will be extremely valuable for monitoring in vivo
release of D-serine (Pernot et al., 2008, 2012; Zain et al., 2010).
These biosensors consist of a thin platinum wire coated with a
semi-permeable layer of poly-m-phenylene-diamine (PPD) and
a layer of DAAO. Degradation of available D-serine is catalyzed
by DAAO, generating hydrogen peroxide that is oxidized at the
surface of the platinum wire. The resulting hydrogen peroxide
oxidation current corresponds to the D-serine concentration in
the surrounding environment. To date, biosensors implanted in
the rat brain have been used to detect D-serine in vivo (Zain et al.,
2010; Pernot et al., 2012). Alternatively, the temporal resolution of
in vivomicrodialysis has been recently improved to the point that it
is now possible to detect D-serine levels with a resolution of several
seconds (Rosenberg et al., 2010). Additional studies determining
what factors inﬂuence andmodulate D-serine levels in vivo are sure
to follow shortly.
D-SERINE IS A CRITICAL PLAYER IN NMDAR-MEDIATED SYNAPTIC
PLASTICITY
NMDARs are unique in that they require the binding of two ago-
nists to be fully functional. In particular, activation of NMDARs
requires the binding of glutamate to the GluN2 subunit as well
as the binding of a separate co-agonist to the glycine site of the
GluN1 subunit (Johnson and Ascher, 1987). While D-serine was
originally identiﬁed as an effective co-agonist of the NMDAR
(Kleckner and Dingledine, 1988), glycine was thought to be a
more likely endogenous candidate because, at the time, more
was known about its presence in mammalian brain. In light
of the considerable accumulation of evidence that D-serine is
indeed present in many mammalian brain areas, D-serine has
come to be accepted as an endogenous co-agonist for synap-
tic NMDARs, involved in modulating synaptic transmission and
plasticity. Further support for this idea came from a pioneering
study that monitored NMDAR-mediated synaptic transmission
in hippocampal cell cultures after the selective degradation of
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endogenous D-serine by application of DAAO (Mothet et al.,
2000). It was found that when cells were exposed to DAAO, the
NMDAR currents were signiﬁcantly reduced and this reduction
could be reversed with application of exogenous D-serine. More
recent evidence from Papouin et al. (2012) implicates D-serine as
the endogenous co-agonist speciﬁcally at synaptic NMDARs in the
hippocampus.
As NMDARs are known to be a key player in mediating
excitatory transmission and synaptic plasticity, such as long-term
potentiation (LTP; Constantine-Paton et al., 1990), astrocyte-
derived D-serine is also likely to play an important modulatory
role. Yang et al. (2003) designed an elegant experiment to address
this question in vitro. Speciﬁcally, the ability to evoke LTP in cul-
tured neurons was compared between cells grown in direct contact
with astrocytes and those grown without direct contact. Strikingly,
they found that LTP could not be induced in the neurons that
were not in direct contact with astrocytes unless the cells were
supplemented with an exogenous source of D-serine (Yang et al.,
2003). The important contribution of D-serine to activity-induced
synaptic plasticity has since been further conﬁrmed in other brain
areas including the hypothalamus, retina, and prefrontal cortex
(Panatier et al., 2006; Henneberger et al., 2010; Stevens et al., 2010;
Fossat et al., 2012).
In the hypothalamus, Panatier et al. (2006) took advantage of
the fact that the physical association of astrocytes with neurons
in the supraoptic nucleus (SON) changes during pregnancy. In
particular, during lactation the release of the hormone oxytocin
causes a retraction of astrocytic processes from synaptic sites in the
SON,which results in a decrease in available D-serine at the synap-
tic cleft. Panatier et al. (2006) found a corresponding decrease in
NMDAR-mediated synaptic activity as well as an increase in the
threshold required to induce LTP in the SON.
More recently, Henneberger et al. (2010) have extended these
ﬁndings by providing evidence that the release of D-serine
from astrocytes in the hippocampus is likely to be a calcium-
dependent process and that an individual astrocyte can contribute
to NMDAR-dependent plasticity in many surrounding neuronal
synapses. Speciﬁcally, using a technique they developed called
“calcium-clamping” where intracellular astrocytic calcium was
chemically clamped at a ﬁxed concentration, and therefore unable
to ﬂuctuate rapidly, they were able to show that LTP could no
longer be induced in neighboring neurons unless exogenous D-
serine was supplemented. A similar result was obtained by loading
astrocytes with tetanus toxin to prevent VAMP-dependent vesic-
ular release. Notably, they also showed that one astrocyte in the
hippocampus appeared to be responsible for a speciﬁc territory
of neighboring neurons and that neurons found outside of this
speciﬁc area (i.e., >200 μm) were unaffected by these manipu-
lations. These speciﬁc ﬁndings were somewhat surprising since
the anatomical territory of an astrocyte in the hippocampus is
generally considered to be only about 50–100 μm large, raising
the possibility that communication between adjacent astrocytes
may participate in this phenomenon.
An interesting feature of NMDARs is that they are found both
synaptically and extrasynaptically. The NMDAR has been shown
to have different physiological functions depending on its loca-
tion. While NMDARs found at synapses have a well-established
role in mediating synaptic LTP, extrasynaptic NMDARs have been
implicated in other forms of plasticity, as well as in the pathogen-
esis of certain neurodegenerative diseases including Huntington’s
and Alzheimer’s disease (Kaufman et al., 2012).
Recent results have shed some light as to why synaptic
versus extrasynaptic NMDARs may have distinct physiologi-
cal functions. Papouin et al. (2012) have shown that synaptic
and extrasynaptic NMDARs in the hippocampus preferentially
bind different co-agonists. In particular, by applying enzymes
to selectively degrade either D-serine or glycine they were
able to demonstrate that D-serine preferentially affects synap-
tic NMDARs whereas glycine preferentially affects extrasynaptic
receptors. When D-serine was degraded using DAAO, synapti-
cally mediated NMDAR functions, including LTP, were abolished.
Conversely, the application of glycine oxidase, an enzyme that
speciﬁcally degrades glycine, had no effect on synaptic excitatory
potentials.
N-methyl-D-aspartate receptor afﬁnity for binding D-serine
versus glycine depends on its GluN2 subunit composition. While
NMDARs composed of GluN2A subunits exhibit a high afﬁnity
for D-serine, NMDARs composed of GluN2B subunits preferen-
tially bind glycine (Madry et al., 2007). Papouin et al. (2012) took
advantage of the existence of antagonists with preferential afﬁni-
ties for GluN2A and GluN2B to further determine the respective
contributions of D-serine and glycine in regulating synaptic versus
extrasynaptic NMDAR activation. They found that NMDAR-
mediated post-synaptic potentials were reduced in the presence
of free Zn, an antagonist of GluN2A-containing receptors, but
were unaffected in the presence of Ro25-6981, a selective GluN2B
antagonist. To study the endogenous co-agonist of extrasynaptic
NMDARs, synaptic receptors were silenced using MK801. Under
synaptic NMDAR blockade, the spared extrasynaptic NMDA-
evoked responses were decreased when glycine was speciﬁcally
degraded. These results indicate that that while D-serine is an
important co-agonist of synaptic NMDARs, glycine may function
as the principal partner for extrasynaptic receptors.
DEVELOPMENTAL EXPRESSION OF D-SERINE AND THE DEVELOPMENT
OF GLUTAMATERGIC SYNAPSES
During early development neurons undergo extensive synaptic
reﬁnement and maturation as they establish functional neu-
ronal circuits. It has been well-established that NMDARs play a
critical role in the development of neuronal circuits. Blocking
their activity has been shown in many cases to disrupt nor-
mal activity-dependent map formation (Constantine-Paton et al.,
1990; Ruthazer and Cline, 2004; Espinosa et al., 2009; Erzurumlu
and Gaspar, 2012).
Immunohistochemical localization studies of D-serine in rat
brain have illustrated that D-serine levels change over different
stages of development. For example, the VN, an area specialized
in controlling balance and spatial orientation, have high levels of
D-serine during the ﬁrst 3 weeks of post-natal development, which
gradually decrease with age (Puyal et al., 2006). Furthermore, in
the cerebellum, a brain region important for motor coordina-
tion and learning, D-serine levels are high during the ﬁrst weeks
after birth but then rapidly decline to almost undetectable lev-
els by P26. As in other brain areas, D-serine has been localized
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within speciﬁc glia cells bodies of the cerebellum. In particular,
high levels of D-serine are found in the radial processes and end
feet of Bergmann glia surrounding Purkinje cell dendrites (Schell
et al., 1997; Wolosker et al., 1999). Notably, the drop in D-serine
levels parallels the increase in expression of DAAO in cerebellum
(Weimar and Neims, 1977; Horiike et al., 1987).
During early post-natal development the cerebellumundergoes
a series of important developmental changes that are essential for
forming a functional cerebellar circuit. It is a time when parallel
and climbing ﬁbers form stereotypic synaptic connections with
Purkinje cells. This establishment of functional synapses has been
shown to be dependent on NMDARs since blocking the recep-
tors prevents the formation of proper synapses (Rabacchi et al.,
1992). Given the tight physical interaction between Bergmann glia
and Purkinje cells it has been proposed that D-serine release from
Bergmann glia may be an important player in the development of
functional synapses in the cerebellum (Schell et al., 1997), however,
the speciﬁc involvement of D-serine in establishing connections in
the cerebellum remains to be examined. Consistent with the idea
that D-serine may play a role in promoting the formation of func-
tional synapses is the recent evidence that synaptogenesis induced
by transforming growth factor β-1 (TGF-β1) is dependent on D-
serine (Packard et al., 2003; Diniz et al., 2012). In cultured neurons
Diniz et al. (2012) have shown that TGF-β1 secreted from astro-
cytes promotes the NMDAR-dependent formation of synapses.
Interestingly, in addition to inducing synaptogenesis, TGF-β1 also
results in an increase in extracellular levels of D-serine. Further-
more, application of D-serine alone was sufﬁcient to induce the
formation of synapses, similar to TGF-β1 treatment. The synap-
togenic property of TGF-ß1 was eliminated when D-serine was
reduced by DAAO treatment, suggesting that D-serine release is
responsible for TGF-β1-mediated synaptogenesis.
The development and reﬁnement of functional neuronal cir-
cuits is mediated, at least in part, by neurotrophins. In particular,
brain-derived neurotrophic factor (BDNF) has been found to
be an activity-regulated neurotrophin that plays a key role in
promoting synapse formation and maturation and in regulating
the functional development of neuronal circuits (Huang et al.,
1999; Kaneko et al., 2008; Cohen-Cory et al., 2010; Schwartz
et al., 2011; Park and Poo, 2012). Consistent with evidence that
NMDAR activation can regulate BDNF production, a recent
study found that SR knockout mice (SR−/−) have a reduction in
total BDNF protein levels (Balu et al., 2012). This result further
underscores the importance of D-serine as a potential media-
tor in the establishment of precise neuronal connections during
development.
The subunit composition of NMDARs changes over develop-
ment and by brain region, suggesting that NMDAR subtypes may
play different developmental roles. In the hippocampus GluN2B
expression peaks early in development while GluN2A expres-
sion occurs later. This shift in GluN2A/2B subunit expression
has been correlated with the maturation of neuronal circuits
and the control of a number of important developmental events
(van Zundert et al., 2004; Yashiro and Philpot, 2008). For
example, in the rodent visual cortex the developmental switch
from GluN2B to GluN2A is delayed by extended dark-rearing
(Quinlan et al., 1999).
Recent evidence has shown that the availability of D-serine
and glycine preferentially inﬂuences the diffusion of NR2B versus
NR2A subunits (Burnet et al., 2011; Papouin et al., 2012), suggest-
ing that D-serine may play a role in the development of neuronal
circuits potentially by inﬂuencing the subunit make-up of gluta-
matergic synapses. Experiments by Papouin et al. (2012) revealed
that, increasing the amounts of D-serine or glycine selectively
inhibited surface trafﬁcking of GluN2B and GluN2A, respectively.
The mechanisms by which D-serine and glycine inhibit the dif-
fusion of GluN2A or 2B are unknown, however, conformational
changes in the receptor have been proposed as a means by which
diffusion could be prevented. Furthermore, a DAAO knockdown
in mouse cerebellum, resulting in elevated D-serine levels has been
shown to lead to a decrease in GluN2A mRNA levels (Burnet
et al., 2011). These experiments reveal that D-serine and glycine
exert a surprising degree of control over functional NMDAR sub-
unit composition at multiple levels, ranging from synthesis to
trafﬁcking to activation.
D-SERINE AND THE DEVELOPMENT OF DENDRITIC MORPHOLOGY
NMDARs are required for the proper development of dendritic
arbors. NMDARblockade in the developing brain results in a dras-
tic decrease in dendritic growth (Rajan and Cline, 1998; Sin et al.,
2002). Recently, the importance of D-serine in mediating normal
dendritic development has been examined in SR−/− mice (DeVito
et al., 2011; Balu and Coyle, 2012). The dendrites of pyramidal
neurons in prefrontal cortex, as well as primary somatosensory
cortex, of SR−/− mice are less complex and have a shorter total
length (Balu et al., 2012). SR−/− animals have a small but signif-
icantly reduced cortical volume. As expected, the dendritic arbor
changes were not as severe when neuronal SR was deleted in older
mice after weaning, indicating that there is an early post-natal
critical period in which SR is most effective in affecting den-
dritic development. The relative contributions of neuronal and
astrocytic SR to normal dendritic development and maintenance
remain to be fully explored.
NEURONAL MIGRATION
In addition to its important role in the formation and matu-
ration of synaptic contacts, D-serine has been demonstrated to
contribute to earlier stages neuronal circuit construction, as a
regulator of neuroblast migration in the developing brain. High
levels of D-serine have been localized in the radial processes and
end feet of Bergmann glia surrounding Purkinje cell dendrites
(Schell et al., 1997; Wolosker et al., 1999). During the period of
early post-natal development the cerebellum undergoes a series of
important developmental changes that are essential for forming
a functional cerebellar circuit. Granule cells, the primary excita-
tory neurons in the cerebellar circuit, migrate from the external
to internal granule cell layer and this migration processes has
been shown to occur along radial glial cells which give rise to
Bergmann glia.
The completion of granule cell migration has been found
to correspond to decreasing levels of D-serine suggesting that
D-serine may be an important player in the granule cell migra-
tion process. Indeed, Kim et al. (2005) found that when D-serine
was degraded by DAAO this resulted in a reduction in neuronal
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migration by ∼60%, which could be reversed with application of
exogenous D-serine. Furthermore, inhibition of SR also was found
to result in a reduction inmigration. Overall, the evidence suggests
that D-serine acts as chemokinetic stimulus to granule cells (Kim
et al., 2005).
The cerebellum is a clear and well-studied example of a brain
area where neurons migrate along glia to reach their mature
position in an organized neuronal circuit. However, radial cell
migration is not limited to the cerebellum and thus it will be
interesting to further determine how D-serine may be involved in
neuronal migration in other brain areas that depend on directed
migration, such as neocortex.
D-SERINE AND DISORDERS OF GLUTAMINERGIC FUNCTION
D-serine has emerged as an inﬂuential player in the context of
psychiatric disease. Motivated in large part by the hypothesis
that schizophrenia and depression may represent dysregula-
tion of glutamatergic systems, with a particular emphasis on
NMDAR transmission (Carlsson and Carlsson, 1990; Bennett,
2009; Gunduz-Bruce, 2009), there has been an increasing number
of studies exploring D-serine, both endogenously as a potential
cause and exogenously as a potential therapy for these disease
conditions.
SCHIZOPHRENIA
Schizophrenia is characterized by disintegration of thought pro-
cesses and emotional responsiveness (Lewis and Lieberman, 2000;
van Os and Kapur, 2009). The etiology of schizophrenia is
believed to involve a combination of genetic and environmental
factors. Schizophrenia symptoms can be categorized as pos-
itive and negative: positive symptoms include delusions and
hallucinations whereas negative symptoms include anhedonia,
asociality, alogia, avolition, and blunted emotional response.
In addition, schizophrenia patients suffer from varying degrees
of cognitive deﬁcit. A model of glutaminergic hypofunction
with accompanying disinhibition of the dopaminergic system
has gained signiﬁcant support (Carlsson and Carlsson, 1990;
Lisman et al., 2008; Bennett, 2009; Gunduz-Bruce, 2009). This
hypothesis, which proposes that NMDAR hypofunction may be
responsible in part for schizophrenia, is premised upon the obser-
vation that NMDAR antagonists like phencyclidine (PCP) and
ketamine are able to induce a wide spectrum of schizophrenia-
like symptoms in normal human subjects (Javitt and Zukin,
1991; Krystal et al., 1994; Coyle, 1996; Olney et al., 1999).
This hypothesis initially led to the use of D-serine as a poten-
tial therapeutic for alleviating schizophrenia (Contreras, 1990).
Subsequently, a deﬁciency in endogenous D-serine availabil-
ity was proposed as a potential underlying cause of NMDAR
hypofunction.
Consistent with this hypothesis, several studies have revealed a
reduction in D-serine levels in the plasma and cerebrospinal ﬂuid
of schizophrenic patients (Hashimoto et al., 2003; Bendikov et al.,
2007; Calcia et al., 2012). Thismaybe explained in part by excessive
degradation of D-serine, as supported by observations that DAAO
levels and activity have been found to be elevated in post-mortem
hippocampus and cortex samples from schizophrenia patients
(Madeira et al., 2008; Habl et al., 2009).
Association studies have identiﬁed several mutations in human
D-serine metabolic enzymes as risk factors for schizophrenia.
These include single-nucleotide polymorphism (SNP) variants
of SR (Morita et al., 2007), DAAO (Boks et al., 2007; Caldinelli
et al., 2013), and the DAAO interacting protein G72 (Muller et al.,
2011). Notably, the schizophrenia and depression susceptibility
gene Disrupted in schizophrenia-1 (DISC1) appears to directly
bind SR, protecting it from ubiquitin-mediated degradation (Ma
et al., 2012).
D-serine, as an NMDAR co-agonist, has been tested as a
potential therapeutic agent for schizophrenia. D-serine, in com-
bination with antipsychotics, was reported to be more efﬁcient
in relieving numerous symptoms of schizophrenia than antipsy-
chotics on their own (Tsai et al., 1998; Heresco-Levy et al., 2005;
Kantrowitz et al., 2010). In mice, D-serine successfully reversed
schizophrenia-like symptoms, such as the reduction in prepulse
inhibition and certain cognitive deﬁcits, caused by administra-
tion of NMDAR antagonists (Lipina et al., 2005; Hashimoto et al.,
2008; Kanahara et al., 2008). However, chronic administration of
D-serine can result in desensitization as well as kidney damage
in patients. Thus, a number of alternative NMDAR glycine site
agonists have been tested. The antibiotic D-cycloserine and a syn-
thetic amidated tetrapeptide GLYX-13 are both partial agonists of
the NMDAR glycine site and therefore do not function identically
to the full agonist D-serine (Kanahara et al., 2008; Zhang et al.,
2008). The assessment of D-cycloserine effects in schizophrenia
patients has not been straightforward (Duncan et al., 2004). It
has been proposed that D-cycloserine may only be efﬁcient when
used in treatment together with a training paradigm (Gottlieb
et al., 2011). Glycine, also a full agonist at the NMDAR glycine
site, has been reported to relieve negative and positive schizophre-
nia symptoms in patients and to do so more efﬁciently than
D-cycloserine (Heresco-Levy and Javitt, 2004). A meta-analysis
reviewing a multitude of trials with schizophrenia patients receiv-
ing D-serine, glycine and D-cycloserine came to the conclusion that
the full agonistsweremore effective at relievingnegative symptoms
of schizophrenia than D-cycloserine, but that no glutaminergic
therapy successfully attenuated the positive symptoms (Tuominen
et al., 2005).
DEPRESSION AND D-SERINE
The etiology of mood disorders [major depressive disorder
(MDD), bipolar disorder and dysthymic disorder] is also not well-
understood (Hidaka, 2012). MDD constitutes a disturbance of
mood accompanied by a selection of psychophysiological changes,
such as slowing of speech and action, insomnia or hypersom-
nia, fatigue, psychomotor agitation or retardation, and loss or
increase of appetite (Cassano and Fava, 2002; Belmaker and
Agam, 2008). Common psychological symptoms include loss
of concentration, perfectionism/obsessiveness, increased sensi-
tivity to criticism, feelings of worthlessness, anhedonia, and
suicidal thoughts (Cassano and Fava, 2002). MDD is currently
one of the leading causes of disability worldwide (Hidaka,
2012). MDD is generally considered to reﬂect a malfunction of
the monoaminergic systems, but growing evidence also points
toward the involvement of excitatory amino acids (Kugaya and
Sanacora, 2005). Altered, usually elevated, levels of glutamate
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metabolites have been detected in post-mortem human prefrontal
cortex (Hashimoto et al., 2007) and blood serum (Mauri et al.,
1998). A proton magnetic spectroscopy study, which enabled
quantiﬁcation of glutamate and GABA levels in live depression
patients, also revealed higher than normal glutamate concen-
trations in the prefrontal cortices of MDD patients, together
with an abnormal inhibitory/excitatory neurotransmitter ratio
(Sanacora et al., 2004).
Chronically stressed animals, considered to be a model for
depression, exhibit profound changes in neuroplasticity, specif-
ically impairment in hippocampal and prefrontal cortical LTP
induction, and a facilitation of spike-timing dependent long-term
depression (Shors et al., 1990; Shors, 2004; Pittenger and Duman,
2008; Marsden, 2013). Chronic restraint stress was shown to result
in NMDAR-dependent dendritic atrophy in rat medial prefrontal
cortex, that could be prevented by CPP administration (Martin
and Wellman, 2011). The evidence for NMDAR involvement in
animal depression models inspired the testing of NMDAR binding
compounds. MK-801, AP-7, and 1-aminocyclopropanecarboxylic
acid (ACPC) were all found to be as effective as common
antidepressants in increasing the performance of mice in stress
paradigms like the forced swim and the tail suspension test
(Trullas and Skolnick, 1990). Ketamine has been repeatedly
shown to relieve depression and anxiety in about 70% of human
patients (Sappington et al., 1979; Zarate et al., 2006; Diazgranados
et al., 2010).
Interestingly, whereas ketamine, MK-801 and AP-7 are all
NMDAR antagonists, ACPC is a partial agonist for the NMDAR
glycine site. Subsequently D-serine was tested on the so-called
“Flinders Sensitive rat” strain that displays symptoms similar to
humandepression patients, for example reduced interest in reward
and increased fear response (Overstreet et al., 2005). This rodent
model for depression exhibits increased hippocampal glutamater-
gic activity. Its hippocampi appear to contain lower than normal
levels of D-serine, as measured by enantioselective chromatogra-
phy, perhaps due to a homeostatic compensation for the elevated
glutamate, and are impaired for CA1 LTP induction. Flinders
Sensitive rats were found to have worse object-recognition mem-
ory, which could be rescued by an acute injection of D-serine
(Gomez-Galan et al., 2012). Similar beneﬁts of acute D-serine
injection were demonstrated in the Wistar Kyoto rat, another
stress-sensitive animal model for depression studies (Malkesman
et al., 2012). Importantly in this latter study, NMDARs in the
forebrain were conﬁrmed as the site of action of the D-serine treat-
ment by demonstrating that rescue was not effective in forebrain
targeted NR1 knockout mice. While it is difﬁcult to distinguish
between a speciﬁc requirement forNMDAR transmission and gen-
eral excitatory transmission, such results provide support for the
idea that disrupted NMDAR function may be an underlying factor
in depression.
COMMON SENSITIVITY TO D-SERINE IN SCHIZOPHRENIA AND
DEPRESSION
It is intriguing to note that while depression is thought to
constitute a hyperglutaminergic condition, relieved by NMDAR
antagonists, schizophrenia is seen as a hypoglutaminergic dis-
ease worsened by NMDAR antagonists. Nonetheless, D-serine
appears to mitigate both of those disorders. Similarly, whereas
low plasma and cerebrospinal ﬂuid (CSF) levels of D-serine are
reported in schizophrenic patients, the Flinders Sensitive ratmodel
for depression also exhibited lower than normal levels of D-serine
in hippocampus. In the latter case, this was speculated to be the
consequence of a protective downregulation of D-serine to spare
neurons from excitotoxic effects in this hyperglutamatergic strain
(Gomez-Galan et al., 2012). Binding of the glycine site on the
NMDAR has been demonstrated to reduce NMDAR desensitiza-
tion (Mayer et al., 1989). Thus, one possible way to reconcile the
paradox of D-serine’s dual efﬁcacy in schizophrenia anddepression
would be if the effects of hyperglutaminergia were in part medi-
ated by NMDAR desensitization, with D-serine both attenuating
desensitization and enhancing neurotransmission.
It is also likely that despite similar outcomes of helping restore
more normal functional states, the major therapeutic targets of
D-serine in schizophrenia and depression are different or at dis-
tinct locations. For example, the main site of dendritic atrophy in
post-mortem samples from schizophrenia patients is reportedly
the prefrontal cortex (Garey et al., 1998; Glantz and Lewis, 2000;
Broadbelt et al., 2002; Garey, 2010), whereas in chronically stressed
animals, spine and dendrite loss is mostly observed in hippocam-
pus (Magarinos and McEwen, 1995; Magarinos et al., 1996; Luo
and Tan, 2001; Chen et al., 2008; Bedrosian et al., 2011) and in
some cases in prefrontal cortex (Cook and Wellman, 2004; Martin
and Wellman, 2011). Hippocampal neuropil damage is supported
by magnetic resonance imaging (MRI) studies in humans suf-
fering from depression (Sheline et al., 1999; von Gunten et al.,
2000; Stockmeier et al., 2004; MacQueen et al., 2008). Based on
the important contributions of D-serine to normal dendrite for-
mation during development (DeVito et al., 2011; Balu and Coyle,
2012; Balu et al., 2012), it offers great promise as a potential
means for helping restore normal dendritic structure and func-
tion in schizophrenia and depression, albeit in heterogenous brain
areas.
APPLICATIONS OF D-SERINE THERAPY IN OTHER DISEASES
Due to the success of D-serine treatment in relieving symp-
toms of schizophrenia, its use has been extended to treat a
variety of diseases. NMDAR antagonists have been effective in
ameliorating Parkinsonian symptoms in animal models (John-
son et al., 2009). A pilot study involving 10 Parkinson disease
patients treated with 30 mg/kg D-serine for 6 weeks in addi-
tion to their usual medications demonstrated improvements in
motor and behavioral deﬁcits (Gelﬁn et al., 2012). Using an
identical treatment regimen, the same group reported anxiolytic
properties for D-serine in a group of 22 post-traumatic stress
disorder patients (Heresco-Levy et al., 2009). D-cycloserine has
been found to have anxiolytic properties in patient cohorts with
different phobias or obsessive-compulsive disorder. Interestingly,
D-cycloserine seems to be effective only when combined with
exposure therapy involving the object of fear or obsessiveness
(Kushner et al., 2007; Guastella et al., 2008). Finally, autism
has also been viewed by some as a hypoglutaminergic dis-
order (Carlsson, 1998). In concordance with that idea, high
doses of both D-serine and D-cycloserine were found to improve
the sociability of an inbred Balb/C mouse strain that exhibits
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autism-like behaviors (Jacome et al., 2011; Deutsch et al., 2012).
The pre-clinical glycine site partial agonist GLYX-13 likewise has
been reported to reverse autism-like symptoms in selectively bred
non-social rats (Moskal et al., 2011).
NEURODEGENERATIVE DISORDERS: THE DARK SIDE OF D-SERINE
In addition to alleviating several diseases and conditions, D-serine
may have its dark side in neurodegenerative disease. Amyloid beta
(Aβ) and secreted amyloid precursor protein appear to induce
the release of D-serine and glutamate from cultured microglia
by increasing transcription and stabilization of the microglial SR
(Wu et al., 2004). This could contribute to excitotoxic neuronal
death in Alzheimer’s disease. D-serine may play a similar role in
amyotrophic lateral sclerosis (ALS) where a principal cause for
motoneuron death is considered to be excitotoxicity (Bruijn et al.,
2004). The cerebrospinal ﬂuid of ALS patients has been reported
to contain elevated glutamate levels (Rothstein et al., 1990). Inter-
estingly, it has been observed that spinal cord in the G93A-SOD1
transgenic mouse model for ALS has several-fold higher concen-
trations of D-serine than control animals (Sasabe et al., 2007).
In these mice, D-serine was found to be produced by activated
microglia. The presence of endogenous D-serine has been shown
to be necessary for most, if not all, NMDAR-mediated excitotox-
icity observed in rat brain slices and in vivo (Katsuki et al., 2004;
Hama et al., 2006; Inoue et al., 2008). Pretreatment of rat hip-
pocampal organotypic slices with D-serine deaminase was shown
to practically abolish NMDA-mediated excitotoxicity, suggesting
that D-serine, rather than glycine, participates in these excitotoxic
events in the hippocampus (Shleper et al., 2005). Furthermore,
SR knockout mice exhibited a 50–60% reduction in the volume
of brain damaged in a transient cerebral artery occlusion-induced
strokemodel. These SRknockoutmicewere protected against focal
cerebral ischemia despite a fourfold increase in NR1 subunits and
elevated NMDAR sensitivity (Mustafa et al., 2010). D-serine has
also been hypothesized to participate in epileptogenesis. In ani-
malswith pilocarpine-induced epilepsy increased D-serine content
in astroglia or neurons, but interestingly not microglia, has been
reported (Liu et al., 2009).
SUMMARY
Once thought to have no neurological signiﬁcance, D-serine is
now recognized as an important player in normal brain devel-
opment and function. D-serine is localized in areas of the brain
that have high NMDAR expression and is considered to be an
important endogenous co-agonist of NMDARs in many brain
regions, including the forebrain and hippocampus. D-serine reg-
ulates NMDAR-mediated synaptic transmission and plasticity. It
has also been shown to be a key mediator in neuronal migration in
the cerebellum. Just as our understanding of the various roles for
D-serine in brain development has grown more sophisticated, our
comprehension of the mechanisms underlying D-serine synthesis
and release has also evolved. It has been proposed that neurons,
which contain high SR,may play an important role in synthesizing
D-serine while glial cells appear to play a more important role in
its release (Figure 2). Still, our understanding of the speciﬁc roles
of neuronal versus glial D-serine remain incomplete. Progress has
beenmade using in vitromodels, but the key issue of how signaling
events inﬂuence andmodulate D-serine levels in vivo is still an open
question. Overall, there is a great deal of accumulated evidence
implicating D-serine as an important player in neuronal develop-
ment, however, its speciﬁc roles in the reﬁnement of functional
neuronal circuits remains to be fully explored.
In light of its critical role in the normal development of neu-
ronal circuits, it is hardly surprising that D-serine also participates
in adult psychiatric health. D-serine regulation has been inves-
tigated extensively as a causative factor and in some cases as a
potential therapeutic in schizophrenia, as well as a broad spec-
trum of other neurological disorders. Curiously, it appears to be
beneﬁcial for both NMDAR hypofunction (schizophrenia) and
hyperfunction (depression) disease models. The explanation for
this might lie in its differential effects on neuronal and glial sub-
populations or in the particular brain regions impacted. It is
tempting to speculate based on the important roles played by
D-serine in the developing brain that its ability to remediate dis-
ease may in part depend on enhancing functional connectivity
by supporting NMDAR-dependent synaptic plasticity, dendritic
arborization, and synaptic transmission in the mature brain.
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